Calliditas Therapeutics (CALT)
(Delayed Data from NSDQ)
$18.70 USD
+1.05 (5.95%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $18.61 -0.09 (-0.48%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
Income Statements
Fiscal Year end for Calliditas Therapeutics AB Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 114 | 80 | 27 | 0 | 20 |
Cost Of Goods | 6 | 2 | 0 | 0 | 0 |
Gross Profit | 108 | 78 | 27 | 0 | 20 |
Selling & Adminstrative & Depr. & Amort Expenses | 143 | 120 | 88 | 41 | 23 |
Income After Depreciation & Amortization | -35 | -42 | -61 | -41 | -3 |
Non-Operating Income | NA | 5 | 2 | 0 | 0 |
Interest Expense | 8 | 4 | 1 | 6 | 1 |
Pretax Income | -43 | -41 | -60 | -48 | -3 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | -1 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -44 | -41 | -59 | -48 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -44 | -41 | -58 | -47 | -3 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -35 | -42 | -61 | -41 | -3 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -35 | -42 | -61 | -41 | -3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.82 | 26.50 | 25.42 | 22.44 | 18.51 |
Diluted EPS Before Non-Recurring Items | -1.64 | -1.54 | -2.29 | -2.11 | -0.19 |
Diluted Net EPS (GAAP) | -1.64 | -1.54 | -2.29 | -2.11 | -0.19 |
Fiscal Year end for Calliditas Therapeutics AB Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 42.45 | 27.25 | 25.59 | 18.29 |
Cost Of Goods | NA | 2.11 | 1.38 | 1.35 | 0.86 |
Gross Profit | NA | 40.57 | 25.87 | 24.24 | 17.43 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 36.63 | 40.63 | 31.38 | 34.65 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.94 | -14.76 | -7.14 | -17.22 |
Non-Operating Income | NA | NA | -0.42 | 0.43 | -2.67 |
Interest Expense | NA | 7.92 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.32 | -15.18 | -6.71 | -19.89 |
Income Taxes | NA | 0.41 | 0.40 | 2.02 | -1.96 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.73 | -15.57 | -8.73 | -17.93 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.73 | -15.57 | -8.73 | -17.93 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 27.01 | 26.81 | 26.88 | 26.87 |
Diluted EPS Before Non-Recurring Items | NA | -0.06 | -0.58 | -0.33 | -0.67 |
Diluted Net EPS (GAAP) | NA | -0.06 | -0.58 | -0.32 | -0.67 |